Venus Remedies receives Rs. 2.50 crore under PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
Executes the first project for developing and manufacturing a novel anticancer mAb
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Subscribe To Our Newsletter & Stay Updated